human growth hormone raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-11-18. Anything still debated is marked as such rather than presented as settled.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
A detailed protocol for the automated monolith–field-flow fractionation method for isolation of extracellular vesicles (including e.g., exosomes and exomeres) was published in 2023. Another area of interest for HPLC is forensics. GC-MS (Gas Chromatography-Mass Spectroscopy) is generally considered the gold standard for forensic analysis. It is used in conjunction with online databases for rapid analysis of compounds in tests for blood alcohol, cause of death, street drugs, and food analysis, especially in poisoning cases. Analysis of buprenorphine, a heroin substitute, demonstrated the potential utility of multidimensional LC as a low-level detection method. HPLC methods can measure this compound at 40 ng/mL, compared to GC-MS at 0.5 ng/mL, but LC-MS-MS can detect buprenorphine at levels as low as 0.02 ng/mL. The sensitivity of multidimensional LC is therefore 2000 times greater than that of conventional HPLC.
Produced by Patrick Uden, directed by Taghi Amirani, made by Uden Associates 6 August New York! New York!, about sewage; New York makes enough sewage each day to fill the Yankee Stadium ten times, with seven million people; it had 80,000 miles of electric cable; a new sewage tunnel 60 miles long, 800 ft below ground, was being built, to be finished in the next century - the New York City Water Tunnel No. 3 is expected to be finished by 2032 13 August Fatal Attraction, about road transport; Britain subsidised rail £2 per mile, West Germany was £5 per mile; Reinhard Gutter of Cologne; traffic calming hadmainly begun in West Germany, from 1976; John Whitelegg; transport psychologist Carina van Knippenburg of the University of Gronigen; in 1987, the Dutch government introduced rationing of car transport, also trialled in Hong Kong; Ian Catling, and road pricing; Martin Paget in Birmingham; Talib Rothengatter, and the resignation of the Dutch government in April 1989; Philip Goodwin; Martin Mogridge of UCL. Narrated by Simon Ward, produced by Stewart Lansley, directed by Andy Mayer, made by Juniper Productions 20 August The Defender, building a new fighter plane in Canada; Chris Ball, of Bristol Aerospace in Winnipeg, and Bob Diemert are building a fighter plane in Carman, Manitoba; Bob Diemert flew one of his restored Hurricane XII aircraft in the 1969 Battle of Britain; the Commemorative Air Force at Harlingen, Texas; his plane attempts to take off, but it is something akin to a scene from Those Magnificent Men in Their Flying Machines.
== Research history == In the early 1900s, chemical messengers were crudely extracted from whole animal brains and tissues and studied for their physiological effects. In 1931, von Euler and Gaddum, used a similar method to try and isolate acetylcholine but instead discovered a peptide substance that induced physiological changes including muscle contractions and depressed blood pressure. These effects were not abolished using atropine, ruling out the substance as acetylcholine. In insects, proctolin was the first neuropeptide to be isolated and sequenced. In 1975, Alvin Starratt and Brian Brown extracted the peptide from hindgut muscles of the cockroach and found that its application enhanced muscle contractions. While Starratt and Brown initially thought of proctolin as an excitatory neurotransmitter, proctolin was later confirmed as a neuromodulatory peptide. David de Wied first used the term "neuropeptide" in the 1970s to delineate peptides derived from the nervous system.
Because of negative effects, the use of opioids for long-term management of chronic pain is not indicated unless other less risky pain relievers have been found ineffective. Chronic pain which occurs only periodically, such as that from neuropathic pain, migraines, and fibromyalgia, is better treated with non-opioid medications. Paracetamol and NSAIDs including ibuprofen and naproxen are considered safer alternatives. They are frequently used combined with opioids, such as paracetamol combined with oxycodone (Percocet) and ibuprofen combined with hydrocodone (Vicoprofen), which boosts the pain relief but is also intended to deter recreational use.
Sources: en.wikipedia.org
=== GLMA: Health Professionals Advancing LGBTQ Equality === GLMA: Health Professionals Advancing LGBTQ Equality is the world's largest and oldest LGBTQ healthcare professionals association founded in 1981. It is also formerly known as the Gay and Lesbian Medical Association. GLMA provides resources along with educational programs to help healthcare professionals gain the knowledge and skills in giving appropriate care to LGBTQ patients whilst hosting conferences and workshops to foster the environment for discussion of the latest research or emerging issues in the field. They also conduct LGBTQ centered research to identify the disparities and health needs to publish guidelines and inform about evidence-based healthcare practices and policies to LGBTQ health.
Autologous: The donor skin is taken from a different site on the same individual's body (also known as an autograft). Isogeneic: The donor and recipient individuals are genetically identical (e.g., monozygotic twins, animals of a single inbred strain; isograft or syngraft). Allogeneic: The donor and recipient are of the same species (human→human, dog→dog; allograft). Xenogeneic: The donor and recipient are of different species (e.g., bovine cartilage; pig skin; xenograft or heterograft). Prosthetic: Lost tissue is replaced with synthetic materials such as metal, plastic, or ceramic (prosthetic implants). Allografts, xenografts, and prosthetic grafts are usually used as temporary skin substitutes, that is a wound dressing for preventing infection and fluid loss. They will eventually need to be removed as the body starts to reject the foreign material. Autologous grafts and some forms of treated allografts can be left on permanently without rejection. Genetically modified pigs can produce allograft-equivalent skin material, and tilapia skin is used as an experimental cheap xenograft in places where porcine skin is unavailable and in veterinary medicine. By thickness:
The four substrates of this enzyme are 3-hydroxybenzenepropanoic acid, reduced nicotinamide adenine dinucleotide (NADH), oxygen, and a proton. Its products are 2,3-dihydroxyphenylpropionic acid, oxidised NAD+, and water. It is a flavoprotein that uses flavin adenine dinucleotide as a cofactor. The enzyme can act on related substrates, for example to convert 3'-hydroxycinnamic acid to 2,3-dihydroxycinnamic acid:
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.